Mylan Institutional, Inc. (D.B.A. UDL Laboratories) FDA Record
- 1 Class I recall
- No warning letters matched by name
Mylan Institutional, Inc. (D.B.A. UDL Laboratories) has 22 FDA recalls (1 Class I), 0 inspections, 0 510(k) clearances and 0 compliance actions on record. No FDA warning letter addressed to "Mylan Institutional, Inc. (D.B.A. UDL Laboratories)" is on file.
- Latest recall
- D-0860-2022 · Class II · Apr 1, 2022
Summary
| Records | Count | Last refreshed | Source as of | Status |
|---|---|---|---|---|
| Recalls | 22 (1 Class I) | Nov 15, 2026 | File dated Nov 10, 2026 | Current |
| 510(k) clearances | 0 | Nov 15, 2026 | File dated Nov 9, 2026 | Current |
| Inspections | 0 | Nov 17, 2026 | Newest record Nov 9, 2026 | Current |
| Compliance actions | 0 | Nov 2, 2026 | Newest record Oct 29, 2026 | Current |
FDA record by year
Mylan Institutional, Inc. (D.B.A. UDL Laboratories): FDA recall records per year
| Year | Inspections | OAI | Warning letters | Recall records | Class I |
|---|---|---|---|---|---|
| 2026 | 0 | 0 | 0 | 0 | 0 |
| 2025 | 0 | 0 | 0 | 0 | 0 |
| 2024 | 0 | 0 | 0 | 0 | 0 |
| 2023 | 0 | 0 | 0 | 0 | 0 |
| 2022 | 0 | 0 | 0 | 2 | 0 |
| 2021 | 0 | 0 | 0 | 0 | 0 |
| 2020 | 0 | 0 | 0 | 0 | 0 |
| 2019 | 0 | 0 | 0 | 1 | 0 |
| 2018 | 0 | 0 | 0 | 3 | 0 |
| 2017 | 0 | 0 | 0 | 2 | 0 |
Reviewing Mylan Institutional, Inc. (D.B.A. UDL Laboratories) as a supplier? Request a free FDA snapshot: name up to five suppliers and get a PDF of their public FDA record, with sources and dates. You do not need an API connection. Each snapshot is prepared by hand.
Or check Mylan Institutional, Inc. (D.B.A. UDL Laboratories) yourself in Claude, Cursor or ChatGPT: get the full FDA risk summary, with inspections, warning letters, Form 483s and import alerts by site.
Recent recalls
| Number | Class | Product | Date |
|---|---|---|---|
| D-0860-2022 | Class II | Esomeprazole Magnesium Delayed-Release Capsules, USP 20 mg, packaged in Unit Dose Blister Cards of 6… | Apr 1, 2022 |
| D-0861-2022 | Class II | Esomeprazole Magnesium Delayed-Release Capsules, USP 40 mg, packaged in Unit Dose Blister Cards of 6… | Apr 1, 2022 |
| D-1013-2019 | Class II | Alprazolam Tablets, USP, 0.25 mg, 10x10 per carton, Rx Only, Manufactured for: Mylan Pharmaceuticals… | Jan 18, 2019 |
| D-1112-2018 | Class III | Diltiazem HCl Extended-release Capsules, USP 120 mg, 80 capsules, 8 blister cards of 10 capsules… | Aug 14, 2018 |
| D-0823-2018 | Class II | Loxapine Capsules, USP 50 mg, packaged in 100 Unit Dose capsules, Rx only, Manufactured by Mylan… | May 1, 2018 |
| D-0822-2018 | Class II | Loxapine Capsules, USP 25 mg, packaged in 100 Unit Dose Capsules, Rx only, Manufactured by Mylan… | May 1, 2018 |
| D-0622-2017 | Class II | Atorvastatin Calcium Tablets, 10 mg*, 100-count Unit Dose Tablets (10 x 10) per carton, Rx only… | Mar 21, 2017 |
| D-0493-2017 | Class II | Mirtazapine Tablets, USP, 45 mg. Rx only, 100 Tablets (10 X 10). Manufactured by: Mylan… | Jan 27, 2017 |
| D-0136-2017 | Class III | Clonazepam Tablets, USP, 1.0 mg, packaged in a 100- count unit dose box of 10 x 10 blister cards, Rx… | Sep 28, 2016 |
| D-0135-2017 | Class III | Clonazepam Tablets, USP, 0.5 mg, packaged in a)100- count unit dose box of 10 x 10 blister cards… | Sep 28, 2016 |
| D-0650-2016 | Class III | Clonazepam Tablets, USP, 0.5 mg, 100-count carton, Rx only, Manufactured by Mylan Pharmaceuticals… | Jan 28, 2016 |
| D-0235-2016 | Class III | Meclizine Hydrochloride Tablets, USP, 25 mg Tablets, Packaged in 10 x 10 Tablet Blister Pack… | Nov 2, 2015 |
| D-1083-2015 | Class III | Fexofenadine Hydrochloride Tablets, USP 60 mg, Allergy, Non-Drowsy, Antihistamine, 100 tablets (10 X… | Mar 26, 2015 |
| D-1435-2014 | Class III | Diltiazem HCl Extended-release Capsules, USP, 120 mg, packaged in 80 Capsules (8 x 10) blister cards… | Jul 3, 2014 |
| D-1155-2014 | Class III | Carisoprodol Tablets, USP, 350 mg, unit dose blister packages of 100 tablets (10 cards of 10 tablets… | Jan 28, 2014 |
| D-0378-2015 | Class II | LAMOTRIGINE TABLETS, 200 mg, 100 Tablets (10 tablets per blister card x 10 blister cards per… | Sep 26, 2013 |
| D-0377-2015 | Class II | CIPROFLOXACIN TABLETS, USP, 500 mg, 100 Tablets (10 tablets per blister card. 10 blister cards per… | Sep 26, 2013 |
| D-1466-2016 | Class II | Amlodipine Besylate Tablets, USP, 2.5 mg*, packaged in a)100-count (10 x 10) unit dose blisters per… | Sep 17, 2013 |
| D-1468-2016 | Class II | Amlodipine Besylate Tablets, USP, 10 mg*, packaged in a) 100-count (10 x 10) unit dose blisters per… | Sep 17, 2013 |
| D-1467-2016 | Class II | Amlodipine Besylate Tablets, USP, 5 mg*, packaged in a) 100-count (10 x 10) unit dose blisters per… | Sep 17, 2013 |
Mylan Institutional, Inc. (D.B.A. UDL Laboratories) and the FDA: common questions
Has Mylan Institutional, Inc. (D.B.A. UDL Laboratories) received an FDA warning letter?
No FDA warning letter addressed to the name "Mylan Institutional, Inc. (D.B.A. UDL Laboratories)" is on file. This answer covers that name only: letters addressed to a related company name or to one of its sites are listed on that name's or site's own page.
Has Mylan Institutional, Inc. (D.B.A. UDL Laboratories) received an FDA Form 483?
FDA has not published a Form 483 for "Mylan Institutional, Inc. (D.B.A. UDL Laboratories)" in its reading room. FDA publishes some Form 483s, not all of them.
Has Mylan Institutional, Inc. (D.B.A. UDL Laboratories) had an FDA recall?
Yes. Mylan Institutional, Inc. (D.B.A. UDL Laboratories) has 22 FDA recalls on record, 1 of them Class I, the most serious class. The most recent started Apr 1, 2022.
Need more than this page shows? Ask about Mylan Institutional, Inc. (D.B.A. UDL Laboratories) in Claude or ChatGPT and get every site's inspections, Form 483s, warning letters and import alerts, with a link to the FDA source for each record. The API key is free: no card.